Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ANXV Administered as an Intravenous Infusion to Healthy Male Subjects

NCT04850339 is registered in ClinicalTrials.gov with Annexin Pharmaceuticals AB as lead sponsor.

NCT NCT04850339
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04850339 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Ascending Single and Multiple Dose First in Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ANXV Administered as an Intravenous Infusion to Healthy Male Subjects
Lead sponsor
Annexin Pharmaceuticals AB
Phase
Phase 1
Overall status
Completed
Start date
December 21, 2020
Completion date
October 27, 2021
Enrollment
46 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy